Wiley Series in Drug Discovery and Development / Drug Transporters

Transporters CNTs and ENTs 107 Horace T. B. Ho and Joanne Wang 7.1 Introduction 107 7.2 Molecular and Functional Characteristics of CNTs (SLC28) 107 7.3 Molecular and Functional Characteristics of ENTs (SLC29) 112 7.4 Regulation of CNT and ENT Nucleoside Transporters 116 7.5 Physiological and Pathophysiological Functions of CNTs AND ENTs 117 7.6 Therapeutic Significance of CNTs and ENTs 119 7.7 Conclusions and Future Directions 120 Acknowledgment 121 Abbreviations 121 References 121 8 Bile Salt Transporters 127 Jyrki J. Eloranta, Bruno Stieger and Gerd A. Kullak-Ublick 8.1 Overview of the Enterohepatic Circulation of Bile Salts 127 8.2 The Chief Transporters in the Enterohepatic Circulation of Bile Salts 127 8.3 Enterohepatic Bile Salt Transporters in Liver Disease 129 8.4 Control of Bile Salt Transport and Metabolism 130 8.5 N uclear Receptors as Transcriptional Regulators of Bile Salt Homeostasis 130 8.6 FXR-Dependent Mechanisms That Regulate Human Bile Salt Transporter Genes 132 8.7 Cross Talk between the Transcriptional Control of Bile Salt and Drug Transporters 135 8.8 Concluding Remarks and Future Perspectives 135 References 135 9 Multidrug Resistance Protein: P-Glycoprotein 141 Adam T. Clay and Frances J. Sharom 9.1 The P-Glycoprotein Gene Family 141 9.2 Tissue Distribution of P-Glycoprotein 141 9.3 Role of P-Glycoprotein in Human Physiology 141 9.4 P-Glycoprotein Substrates and Modulators 143 9.5 P-Glycoprotein Structure 143 9.6 Subcellular Systems for Studying P-Glycoprotein 146 9.7 ATP Binding and Hydrolysis by P-Glycoprotein 147 9.8 Drug Binding by P-Glycoprotein 148 9.9 P-Glycoprotein-Mediated Drug Transport 148 9.10 Substrate Specificity of P-Glycoprotein and the Nature of the Drug-Binding Site 149 9.11 P-Glycoprotein as a Hydrophobic Vacuum Cleaner or Drug Flippase 150 9.12 Role of the Lipid Bilayer in P-Glycoprotein Function 151 9.13 Mechanism of Action of P-Glycoprotein 153 9.14 Role of P-Glycoprotein in Drug Therapy 154 9.15 Modulation of P-Glycoprotein in Cancer Treatment 154 9.16 Regulation of P-Glycoprotein Expression 155 9.17 P-Glycoprotein Gene Polymorphisms and Their Implications in Drug Therapy and Disease 155 9.18 Summary and Conclusions 156 References 157 10 Multidrug Resistance Proteins of the ABCC Subfamily 161 Anne T. Nies and Thomas Lang 10.1 Introduction 161 10.2 Molecular Characteristics 162 10.3 Functional Properties, Substrate Specificity, and Multidrug Resistance Profiles of Human ABCC/MRPs 163 10.4 Localization of ABCC/MRP Efflux Transporters in Normal Human Tissues and in Human Cancers 167 10.5 Genotype-Phenotype Correlations and Clinical Consequences of Genetic Variants in ABCC Genes 171 10.6 Conclusions and Future Prospects 178 Acknowledgments 179 References 179 11 Breast Cancer Resistance Protein (BCRP) or ABCG2 187 Agnes Basseville, Robert W. Robey, Julian C. Bahr and Susan E. Bates 11.1 Discovery and Nomenclature 187 11.2 ABCG2 Gene and Expression 187 11.3 Physical Properties 191 11.4 Substrates/Inhibitors of ABCG2 194 11.5 Recent Findings in Physiological Function 195 11.6 Predicted Physiological Function from Tissue Distribution 199 11.7 ABCG2 Expression in Cancer and Its Role in Drug Resistance 202 11.8 Genetic Polymorphisms 205 11.9 Conclusion 208 References 208 12 Multidrug and Toxin Extrusion Proteins 223 Stephen H. Wright 12.1 Introduction 223 12.2 Tissue and Subcellular Distribution of MATEs 225 12.3 Functional Characteristics of MATE Transporters 226 12.4 Kinetics and Selectivity of MATE-Mediated Transport 227 12.5 Molecular/Structural Characteristics of MATE Transporters 233 12.6 Regulation of MATE and Activity 236 12.7 Influence of MATEs on Renal OC Clearance and Clinical Drug-Drug Interactions 237 12.8 Conclusions 238 Acknowledgments 238 References 238 13 Drug Transport in the Liver 245 Brian C. Ferslew, Kathleen Köck and Kim L. R. Brouwer 13.1 Hepatic Physiology: Liver Structure and Function 245 13.2 Hepatic Uptake Transport Proteins 245 13.3 Hepatic Efflux Transport Proteins 247 13.4 Regulation of Hepatic Drug Transport Proteins 249 13.5 Disease State Alterations in Hepatic Transport Proteins 253 13.6 Model Systems for Studying Hepatobiliary Drug Transport 255 13.7 Drug Interactions in Hepatobiliary Transport 260 13.8 Interplay between Drug Metabolism and Transport 262 13.9 Hepatic Transport Proteins as Determinants of Drug Toxicity 263 13.10 The Future of Hepatic Drug Transport 263 Acknowledgments 264 References 264 14 Drug Transport in the Brain 273 Tamima Ashraf, Patrick T. Ronaldson and Reina Bendayan 14.1 Introduction 273 14.2 Physiology of the Brain Barriers and Brain Parenchyma 273 14.3 Functional Expression of Drug Transporters in the Brain 274 14.4 Relevance of Drug Transporters in CNS Disorders 283 14.5 Regulation of Drug Transporters by Nuclear Receptors in the Brain 289 14.6 Conclusion 290 References 291 15 Drug Transport in the Kidney 303 Hiroyuki Kusuhara, Takashi Sekine, Naohiko Anzai and Hitoshi Endou 15.1 Introduction 303 15.2 Families of Renal Drug Transporters 305 15.3 Regulation of Renal Drug Transporters 310 15.4 Pharmacokinetic and Pharmacological/Toxicological Aspects 312 15.5 In Vitro Model Systems for Studying Renal Drug Transport 315 15.6 FDA and EMA Draft Guidance/Guideline for Drug-Drug Interaction Studies 316 15.7 Perspectives 316 References 316 16 Drug Transporters in the Intestine 327 Patrick J. Sinko 16.1 Introduction 327 16.2 Intestinal Drug Permeation 327 16.3 Drug Transporters in the Small Intestine 329 16.4 Impact of Small Intestinal Transporters on Oral Absorption of Drugs 331 16.5 Functional Modulation of Intestinal Transporters to Optimize Oral Absorption of Drugs 335 16.6 Concluding Remarks 335 References 335 17 Drug Transport in the Placenta 341 Qingcheng Mao, Vadivel Ganapathy and Jashvant D. Unadkat 17.1 Introduction 341 17.2 Blood-Placental Barrier Relevant to Drug Permeability and Transport 341 17.3 Drug Transporters in Human Placenta 342 17.4 Methods to Study Placental Drug Transport 348 17.5 Summary 349 References 350 18 Experimental Approaches to the Study of Drug Transporters 355 Yoshiyuki Kubo, Akira Tsuji and Yukio Kato 18.1 Introduction 355 18.2 In Vivo Experiments 355 18.3 Isolated Tissue Methods 358 18.4 Primary Cell Cultures and Established Model Cell Lines 359 18.5 Membrane Vesicles 362 18.6 Analysis of Drug Interaction Mechanisms 363 18.7 Perspectives 364 References 365 19 Transporters in Drug Discovery: In Silico Approaches 371 Ayman El-Kattan, Manthena V. Varma and Yurong Lai 19.1 Introduction 371 19.2 Physicochemical Determinants of Hepatobiliary Elimination 371 19.3 In Silico Models for Biliary Excretion 373 19.4 Physicochemical Determinants of Renal Elimination 375 19.5 In Silico Models of Renal Excretion 375 19.6 PhysiCochemical Determinants of Brain Penetration 376 19.7 In Silico Approaches and SAR of Clinical Relevant Transporters 377 19.8 Strategies to Assess Transporter Involvement during Drug Discovery 381 19.9 Conclusions 382 References 382 20 Polymorphisms of Drug Transporters and Clinical Relevance 389 Aparna Chhibber, Janine Micheli and Deanna L. Kroetz 20.1 Genetic Variation and Drug Response 389 20.2 Genetic Variation in Membrane Transporters 390 20.3 Functional Analysis of Transporter Variants 391 20.4 Clinical Significance of Transporter Variants 394 References 398 21 Diet/Nutrient Interactions with Drug Transporters 409 Xiaodong Wang and Marilyn E. Morris 21.1 Introduction 409 21.2 Diet/Nutrient Interactions with Drug Transporters 409 21.3 Conclusions 425 Acknowledgments 427 References 427 22 Clinical Relevance: Drug-Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity 433 Serena Marchetti and Jan H. M. Schellens 22.1 Introduction 433 22.2 Interactions Mediated by ABC Drug Transporters 433 22.3 Interactions Mediated by Organic Anion and Cation Transporters (Solute Carrier Family, SLC22) 444 22.4 Interactions Mediated by Peptide Transporters (PEPTs, SLC15) 453 22.5 Interactions Mediated by Multidrug and Toxin Extrusion Transporters (MATEs, SLC47) 455 22.6 Interactions Mediated by Monocarboxylate Transporters (MCTs, SLC16) 457 22.7 Interactions Mediated by Nucleoside (Concentrative and Equilibrative) Transporters (CNTs/ENTs, SLC28/29) 458 22.8 Conclusions 460 References 461 23 Regulatory Science Perspectives on Transporter Studies in Drug Development 473 Sue-Chih Lee, Lei Zhang and Shiew-Mei Huang 23.1 Introduction 473 23.2 Regulatory Science Perspectives on Transporter Studies 474 23.3 Recent FDA NDA Review Examples 483 23.4 Conclusion and Future Directions 486 Acknowledgments 486 Abbreviation List 486 References 487 Index 491